Alumis Inc. (NASDAQ:ALMS) Stock Has Consensus Target Price of $33.27Defense World · Oct 12, 2026
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life MeasuresGlobeNewsWire · Oct 9, 2026
Tango Therapeutics (NASDAQ:TNGX) vs. Alumis (NASDAQ:ALMS) Financial AnalysisDefense World · Oct 6, 2026
Alumis (NASDAQ:ALMS) & Pyxis Oncology (NASDAQ:PYXS) Head-To-Head ReviewDefense World · Sep 16, 2026
Financial Survey: Alvotech (NASDAQ:ALVO) & Alumis (NASDAQ:ALMS)Defense World · Sep 15, 2026
Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 14, 2026Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.77 | -$1.11 | Miss |
| May 14, 2026 | -$0.74 | -$0.74 | Beat |
| Mar 19, 2026 | -$0.97 | -$0.95 | Beat |
| Nov 13, 2025 | -$0.92 | -$1.06 | Miss |
| Aug 13, 2025 | -$1.11 | -$1.17 | Miss |
| May 14, 2025 | -$1.47 | -$1.82 | Miss |